We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Disarming suppressor cells to improve immunotherapy.
- Authors
Whiteside, Theresa L
- Abstract
Human tumors can use many different mechanisms to induce dysfunction in the host immune system. Accumulations of inducible regulatory T cells (iTreg, Tr1) are commonly seen in the tumor microenvironment. These Treg express CD39 and up-regulate CD73 ectonucleotidases, hydrolyze exogenous adenosine triphosphate (ATP) to AMP and adenosine and produce prostaglandin E(2) (PGE(2)). Most tumors also express CD39/CD73 and COX-2 and thus contribute to immune suppression. Pharmacologic inhibitors can be used to eliminate adenosine/PGE(2) production by Tr1 as well as the tumor or to block binding of these factors to their receptors on Teff or to selectively block cAMP synthesis in Teff. These pharmacologic blocking strategies used alone or in combination with conventional treatments or immunotherapies could disarm Tr1, at the same time restoring antitumor functions of Teff.
- Publication
Cancer immunology, immunotherapy : CII, 2012, Vol 61, Issue 2, p283
- ISSN
1432-0851
- Publication type
Journal Article
- DOI
10.1007/s00262-011-1171-7